. Author manuscript; available in PMC: 2014 Oct 2.

Published in final edited form as: J Pharmacogenomics Pharmacoproteomics. 2014 Jan 25;5(1):T-001. doi: 10.4172/2153-0645.T-001

Table 2.

CYP2C9 and VKORC1 variants detected with HILOMet Warfarin system on Luminex^® 100× Map™ technology. Effects on enzymatic activity are also depicted.

CYP2C9			VKORC1
Allelic Variant	Change to Protein	Activity	Allelic Variant	Change to Protein	Activity
*1(WT)	Reference	Normal	WT^#	Reference	Normal
*2 (430C>T)	Arg144Cys	Decreased	−1639 G>A	Promoter	Deficient
*3 (1075A>C)	Ile359Leu	Null	+85 G>T	Val29Leu	Null
*4 (1076T>C)	Ile359Tyr	Decreased	+121 G>T	Ala41Ser	Null
*5 (1080C>G)	Asp360Glu	Decreased	+134 T>C	Val45Ala	Null
*6 (818delA)	Frameshift	Null	+172 A>G	Arg58Gly	Null
			+1331 G>A	Val66Met	Null
			+3487 T>G	Leu28Arg	Null

Wild-types are assigned as a result of the absence of other SNPs.